Published in Aliment Pharmacol Ther on July 01, 2007
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Effectiveness of topical caffeine in cataract prevention: studies with galactose cataract. Mol Vis (2010) 0.92
How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology (2014) 0.89
Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res (2010) 0.89
Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol (2016) 0.84
Pathological roles of purinergic signaling in the liver. J Hepatol (2012) 0.82
Effect of caffeine on the intraocular pressure in patients with primary open angle glaucoma. Clin Ophthalmol (2011) 0.82
Protective effect of caffeine against high sugar-induced transcription of microRNAs and consequent gene silencing: a study using lenses of galactosemic mice. Mol Vis (2013) 0.80
Behavioral and clinical correlates of serum bilirubin concentrations in Japanese men and women. BMC Endocr Disord (2013) 0.80
Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev (2015) 0.78
Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation (2008) 0.77
Putative hepatoprotective effects of coffee. Aliment Pharmacol Ther (2007) 0.75
Coffee and liver - long way to go. J Clin Exp Hepatol (2012) 0.75
Effect of coffee (caffeine) against human cataract blindness. Clin Ophthalmol (2016) 0.75
Obstacles to residents' conducting research and predictors of publication. Acad Med (2001) 2.25
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40
Primary biliary cirrhosis and inflammatory bowel disease. Am J Gastroenterol (1993) 1.39
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 1.22
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant (2006) 1.20
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat (2008) 1.02
Obscure gastrointestinal bleeding from an ampullary tumour in a patient with a remote history of renal cell carcinoma: a diagnostic conundrum. Can J Gastroenterol (1998) 1.01
Massive bleeding from multiple gastric ulcerations in a patient with lymphocytic gastritis and celiac sprue. J Clin Gastroenterol (1997) 0.98
Chinese herbal medicine, fulminant hepatitis, and liver transplantation. Am J Gastroenterol (1996) 0.95
Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol (2000) 0.94
Diminutive but dangerous: a case of a polypoid rectal arteriovenous malformation. Endoscopy (2002) 0.94
Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis (2012) 0.90
Coexisting carcinoid tumors in familial adenomatous polyposis-associated upper intestinal adenomas. Am J Gastroenterol (1999) 0.88
Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology (2006) 0.87
The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol (2008) 0.86
Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation (1997) 0.85
Hepatitis C infection and B-cell non-Hodgkin's lymphoma in British Columbia: a cross-sectional analysis. Ann Oncol (1999) 0.84
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther (2013) 0.84
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther (2008) 0.83
Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann Hepatol (2008) 0.82
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg (1999) 0.82
Primary protein-losing enteropathy in anti-double-stranded DNA disease: the initial and sole clinical manifestation of occult systemic lupus erythematosus? J Clin Gastroenterol (2001) 0.82
Colonic malakoplakia in a liver transplant recipient. Can J Gastroenterol (2007) 0.81
Racial differences between solid organ transplant donors and recipients in British Columbia: a five-year retrospective analysis. Transplantation (1999) 0.81
Impaired exercise performance after successful liver transplantation. Transplantation (2001) 0.80
Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol (1997) 0.80
Late acute rejection occurring in liver allograft recipients. Can J Gastroenterol (1996) 0.80
Correlation between physiological assessment and outcome after liver transplantation. Am J Surg (2000) 0.79
Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients. Transplantation (1997) 0.79
Assessment of immunologic status of liver transplant recipients by peripheral blood mononuclear cells in response to stimulation by donor alloantigen. Ann Surg (1999) 0.78
Aminoglycoside administration as a single daily dose. An improvement to current practice or a repeat of previous errors? Drugs (1996) 0.77
Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada. Can J Gastroenterol (2008) 0.76
Hyperammonemia after heart-lung transplantation. Gastroenterology (1997) 0.76
A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. J Heart Lung Transplant (2001) 0.76
Donor-specific stimulation of peripheral blood mononuclear cells from recipients of orthotopic liver transplants is associated, in the absence of rejection, with type-2 cytokine production. Immunol Lett (1998) 0.76
A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. Am J Transplant (2001) 0.75
The use of interferon-alpha 2B in the treatment of chronic viral hepatitis in patients with preexisting idiopathic thrombocytopenic purpura. Am J Gastroenterol (1995) 0.75
Barriers to transplantation in adults with inborn errors of metabolism. JIMD Rep (2012) 0.75
Orthotopic liver transplantation in a patient with carbamyl phosphate synthetase deficiency and cystic fibrosis. Paediatr Child Health (2003) 0.75
Crohn's disease, HIV, and AIDS. Am J Gastroenterol (1995) 0.75
Lung dysfunction and chronic liver disease. Ann Intern Med (1996) 0.75
Hepatitis C and B-cell non-Hodgkin's lymphoma: a geographically variable association? Am J Med (2000) 0.75
Lovastatin and cholestasis. CMAJ (1993) 0.75
All that bleeds is not infliximab-refractory ulcerative colitis. Can J Gastroenterol (2009) 0.75
Tomorrow's challenge in liver transplantation: diminishing the imbalance between donor organ availability and need. Gut (1998) 0.75
De Novo Crohn's disease in AIDS: Crohn's disease or Crohn's "syndrome"? J Clin Gastroenterol (1998) 0.75
Issues in organ procurement: presumed consent, bioethical type II errors, and organ registries. Ann R Coll Physicians Surg Can (1998) 0.75
Hepatic abscesses after liver transplantation secondary to traumatic intrahepatic bile duct injuries in a cadaveric allograft donor. Transpl Int (2004) 0.75
Diabetes mellitus after liver transplantation: another extrahepatic manifestation of hepatitis C. Can J Gastroenterol (2001) 0.75
Liver enzymes as surrogate markers of hepatitis C histopathology--avoiding the liver biopsy needle? Can J Gastroenterol (2001) 0.75
Carcinoid tumors of the small intestine are uncommon, indolent, slow growing, slow metastasizing, neuroendocrine lesions. World J Surg (1994) 0.75
Assessing virologic efficacy of combination lamivudine and low-dose hepatitis B immune globulin posttransplantation with the ultrasensitive digene hybrid capture II assay. Liver Transpl (2000) 0.75
Post-surgical shunt hepatopulmonary syndrome in a case of non-cirrhotic portal hypertension: lack of efficacy of shunt reversal. Eur J Gastroenterol Hepatol (1999) 0.75
Palliative high-dose octreotide in a case of severe AIDS-related diarrhea. Ann Pharmacother (1994) 0.75
Recurrent hepatocellular carcinoma after liver transplantation mimicking post-transplantation lymphoproliferative disorder. Australas Radiol (2005) 0.75
Peritoneal dialysis after orthotopic liver transplant surgery. Perit Dial Int (2006) 0.75
Primary induction with mycophenolate mofetil and corticosteroids in a liver transplant recipient with hepatorenal syndrome. Ann Pharmacother (1998) 0.75
Acute pseudohepatitis in a chronic substance abuser secondary to occult seat belt injury. Can J Gastroenterol (1999) 0.75
A case of recurrent pyogenic cholangitis. Dig Liver Dis (2007) 0.75
A prediction model for identifying alcohol withdrawal seizures. Am J Drug Alcohol Abuse (1994) 0.75